Acute Lymphoblastic Leukemia Treatment with Dasatinib – Phase III

Intensified Tyrosine Kinase Inhibitor Therapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Protocol Description

The primary goal of this Children’s Oncology Group Phase III study is to determine whether the drug dasatinib, together with combination chemotherapy, may be more effective in treating the specific form of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome positive (Ph+).

Study Level: Phase III

Eligibility Criteria

Subject to certain exclusion criteria, the study is open to individuals of both genders, from age 1 through 21, who have newly diagnosed Ph+ ALL.
Males: Ages 1 through 21 years
Females: Ages 1 through 21 years

Participants will receive the drug dasatinib at specific intervals called for by the protocol along with standard chemotherapy for 131 weeks of treatment.
Duration: About 2.5 years

Status: Open for Enrollment

Source(s) of Support
Children’s Oncology Group (Study AALL0622)
National Cancer Institute
Third Party

Additional Resources
Study Description at National Institutes of Health

Primary Investigator(s)

A. Kim Ritchey, MD

Contact Information

For additional information, please contact:
Jill Visnich

Last Update
February 17, 2014
  • Increase/Decrease Text Size
  • Print This Page
Last Update
February 17, 2014